Abstract | PURPOSE: PATIENTS AND METHODS: Eligible patients had advanced/metastatic breast cancer with at least two prior chemotherapy regimens, including taxane, anthracycline, and capecitabine. A standard 3+3 dose escalation was followed by a phase II expansion. Immunohistochemistry for gpNMB was performed retrospectively for patients with available tumor tissue. RESULTS: Forty-two patients were enrolled. Dose-limiting toxicity (DLT) consisted of worsening neuropathy at 1.34 mg/kg. After excluding patients with baseline neuropathy more than grade 1, no DLT occurred through 1.88 mg/kg (the phase II dose). The phase II primary activity end point was met (12-week progression-free survival [PFS12] = 9 of 27 patients; 33%). Sixteen of 19 (84%) patients tested had gpNMB-positive tumors. At the phase II dose, median PFS was 9.1 weeks for all patients, 17.9 weeks for patients with triple-negative breast cancer (TNBC), and 18.0 weeks for patients with gpNMB-positive tumors. Two patients had confirmed partial responses; both had gpNMB-positive tumors and one had TNBC. CONCLUSION:
Glembatumumab vedotin has an acceptable safety profile. Preliminary evidence of activity in treatment-resistant metastatic breast cancer requires confirmation, such as the phase II randomized trial (EMERGE) that also examines the relationship between activity and gpNMB distribution/intensity.
|
Authors | Johanna Bendell, Mansoor Saleh, April A N Rose, Peter M Siegel, Lowell Hart, Surendra Sirpal, Suzanne Jones, Jennifer Green, Elizabeth Crowley, Ronit Simantov, Tibor Keler, Thomas Davis, Linda Vahdat |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 32
Issue 32
Pg. 3619-25
(Nov 10 2014)
ISSN: 1527-7755 [Electronic] United States |
PMID | 25267761
(Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 by American Society of Clinical Oncology. |
Chemical References |
- Antibodies, Monoclonal
- GPNMB protein, human
- Immunoconjugates
- Membrane Glycoproteins
- glembatumumab vedotin
|
Topics |
- Adult
- Aged
- Alopecia
(chemically induced)
- Anemia
(chemically induced)
- Antibodies, Monoclonal
(adverse effects, immunology, therapeutic use)
- Breast Neoplasms
(drug therapy, metabolism, pathology)
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Therapy
(methods)
- Fatigue
(chemically induced)
- Female
- Humans
- Immunoconjugates
(adverse effects, immunology, therapeutic use)
- Immunohistochemistry
- Membrane Glycoproteins
(immunology, metabolism)
- Middle Aged
- Nausea
(chemically induced)
- Neoplasm Metastasis
- Neutropenia
(chemically induced)
- Treatment Outcome
- Triple Negative Breast Neoplasms
(drug therapy, metabolism, pathology)
|